Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Zydus LifeSciences Shares in Focus: Motilal Oswal Maintains Neutral Rating on Limited Upside — Check Revised Target Price
The current valuation provides limited upside and hence, Motilal Oswal has maintained Neutral rating on Zydus Lifesciences.
Zydus Lifesciences' Rs 1,100 crore share buyback at 13% premium: Check record date, other details
Zydus Lifesciences is launching its largest share buyback program to date. The company plans to repurchase shares worth Rs 1,100 crore. This move offers shareholders a premium price. The record date for eligibility is May 29. The buyback will be conducted through a tender route. This follows previous successful buyback initiatives by the company.
Zydus Lifesciences to pursue acquisitions in specialty, rare diseases
Zydus Lifesciences is set to acquire US firm Assertio Holdings for $166.40 million. This move aims to build a strong specialty oncology business in the US. The company reported robust financial growth for the fourth quarter of 2025-26. Zydus also announced a share buyback and a dividend. Future growth is expected from its specialty portfolio.
Zydus Lifesciences beats estimates, sees high-teens growth in FY27
For FY26, its revenue from operations stood at ₹27,148.4 crore, up 17% on-year, and adjusted net profit grew 15% to ₹5,456.4 crore.
Zydus Life ends higher after Q4 PAT rises 9% YoY; board approves Rs 1,100 cr buyback
Zydus Lifesciences gained 2.80% to end at Rs 1,018.95 after the company's consolidated net profit jumped 8.68% to Rs 1,272.5 crore on 16.22% increase in revenue from operations to Rs 7,587 crore in Q4 FY26 over Q4 FY25.
Zydus Lifesciences consolidated net profit rises 8.68% in the March 2026 quarter
Sales rise 18.19% to Rs 7434.40 crore
Bharat Electronics, BPCL, Mankind Pharma, Zee Entertainment, Zydus Lifesciences Q4 Results Today — Earning Estimates
BPCL is expected to report March-quarter earnings with standalone revenue at Rs 1,17,692.16 crore.
Zydus Lifesciences Ltd soars 2.1%
Zydus Lifesciences Ltd is quoting at Rs 1012.55, up 2.1% on the day as on 12:49 IST on the NSE. The stock is up 12.17% in last one year as compared to a 4.94% drop in NIFTY and a 13.93% drop in the Nifty Pharma index.
Five Stocks To Buy: NMDC, Tata Steel, Varun Beverages And More | May 15, 2026
Top picks include a consensus buy on NMDC, alongside Zydus Lifesciences, Varun Beverages (VBL), Max Healthcare, and Tata Steel.
Market Trading Guide: Buy Zydus Lifesciences, Solar Industries on Friday for gains up to 15%
Nifty 50 closed higher for a second straight session, driven by banking, metal and pharma stocks despite IT weakness. Analysts see 23,800 as a crucial resistance level, while recommending Zydus Lifesciences and Solar Industries India for near-term gains on strong technical indicators and bullish momentum.
Zydus Life spurts as board to mull share buyback; arm signs deal to acquire Assertio
Zydus Lifesciences rallied 5.58% to Rs 991.30 after the company's board is scheduled to meet on Tuesday, 19 May 2026 to consider buyback of fully paid-up equity shares.
Zydus Lifesciences shares jump 6% on buyback buzz; co announces $166 mn Assertio acquisition
Zydus Lifesciences shares witnessed a spike on Thursday after the company said its board will meet on May 19 to consider a share buyback. The stock also gained momentum as Zydus announced a $166 million acquisition of US-based Assertio. Investor sentiment improved on expectations of capital return and strategic business expansion.